CD4 and melanoma: Second, based on the findings that CD4+ T cells in MSI tumor environment express higher levels of PD-1 compared with microsatellite stable (MSS) tumors and CD4+ T cells could recognize mutated antigens in melanoma, they propose CD4+ T cells might play an important role in the anti-PD-1 therapy process [24, 25].